Refine
Year of publication
Document Type
- Article (14)
- Book (1)
- Conference Proceeding (1)
- Doctoral Thesis (1)
- Report (1)
Has Fulltext
- yes (18)
Is part of the Bibliography
- no (18)
Keywords
- ALK-rearranged NSCLC (1)
- Alternsforschung (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer genomics (1)
- Chemotherapy (1)
- Chromosomal deletion (1)
- Deutsch (1)
- Digestive system (1)
- Endoscopy (1)
Institute
- Medizin (12)
- Erziehungswissenschaften (2)
- Biochemie und Chemie (1)
Background: 15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-resection of liver metastases is 28-39%, but recurrence eventually occurs in up to 70%. To date, adjuvant chemotherapy has not improved clinical outcomes significantly. The primary objective of the ongoing LICC trial (L-BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in colorectal cancer patients following R0/R1 resection of hepatic metastases. L-BLP25 targets MUC1 glycoprotein, which is highly expressed in hepatic metastases from colorectal cancer. In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional NSCLC.
Methods: This is a multinational, phase II, multicenter, randomized, double-blind, placebo-controlled trial with a sample size of 159 patients from 20 centers in 3 countries. Patients with stage IV colorectal adenocarcinoma limited to liver metastases are included. Following curative-intent complete resection of the primary tumor and of all synchronous/metachronous metastases, eligible patients are randomized 2:1 to receive either L-BLP25 or placebo. Those allocated to L-BLP25 receive a single dose of 300 mg/m2 cyclophosphamide (CP) 3 days before first L-BLP25 dose, then primary treatment with s.c. L-BLP25 930 mug once weekly for 8 weeks, followed by s.c. L-BLP25 930 mug maintenance doses at 6-week (years 1&2) and 12-week (year 3) intervals unless recurrence occurs. In the control arm, CP is replaced by saline solution and L-BLP25 by placebo. Primary endpoint is the comparison of recurrence-free survival (RFS) time between groups. Secondary endpoints are overall survival (OS) time, safety, tolerability, RFS/OS in MUC-1 positive cancers. Exploratory immune response analyses are planned. The primary endpoint will be assessed in Q3 2016. Follow-up will end Q3 2017. Interim analyses are not planned.
Discussion: The design and implementation of such a vaccination study in colorectal cancer is feasible. The study will provide recurrence-free and overall survival rates of groups in an unbiased fashion. Trial Registration EudraCT Number 2011-000218-20
Background: We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC).
Patients and methods: ALK-rearranged stage IIIB/IV NSCLC patients were analyzed with next-generation sequencing and fluorescence in situ hybridization analyses on a centralized diagnostic platform. Median progression-free survival (PFS) and overall survival (OS) were determined in the total cohort and in treatment-related sub-cohorts. Cox regression analyses were carried out to exclude confounders.
Results: Among 216 patients with ALK-rearranged NSCLC, the frequency of pathogenic TP53 mutations was 23.8%, while other co-occurring mutations were rare events. In ALK/TP53 co-mutated patients, median PFS and OS were significantly lower compared with TP53 wildtype patients [PFS 3.9 months (95% CI: 2.4–5.6) versus 10.3 months (95% CI: 8.6–12.0), P < 0.001; OS 15.0 months (95% CI: 5.0–24.9) versus 50.0 months (95% CI: 22.9–77.1), P = 0.002]. This difference was confirmed in all treatment-related subgroups including chemotherapy only [PFS first-line chemotherapy 2.6 months (95% CI: 1.3–4.1) versus 6.2 months (95% CI: 1.8–10.5), P = 0.021; OS 2.0 months (95% CI: 0.0–4.6) versus 9.0 months (95% CI: 6.1–11.9), P = 0.035], crizotinib plus chemotherapy [PFS crizotinib 5.0 months (95% CI: 2.9–7.2) versus 14.0 months (95% CI: 8.0–20.1), P < 0.001; OS 17.0 months (95% CI: 6.7–27.3) versus not reached, P = 0.049] and crizotinib followed by next-generation ALK-inhibitor [PFS next-generation inhibitor 5.4 months (95% CI: 0.1–10.7) versus 9.9 months (95% CI: 6.4–13.5), P = 0.039; OS 7.0 months versus 50.0 months (95% CI: not reached), P = 0.001).
Conclusions: In ALK-rearranged NSCLC co-occurring TP53 mutations predict an unfavorable outcome of systemic therapy. Our observations encourage future research to understand the underlying molecular mechanisms and to improve treatment outcome of the ALK/TP53 co-mutated subgroup.
Schwermetall-Untersuchungen entlang der Düte und der Hase zeigen die starke Belastung der Auenböden jeweils unterhalb der Städte Georgsmarienhütte bzw. Osnabrück. In den Böden beider Auen erreichen Blei, Zink und Cadmium beträchtliche, die Bodenwerte der AbfKlärVO (1992) z.T. erheblich überschreitende Werte. In den Böden entlang der Hase tritt zudem Kupfer mit besonders hohen Werten auf. Diese Unterschiede stehen in Zusammenhang mit der Art der jeweiligen Industriestandorte (Eisenhütte bzw. Metaliverarbeitung).
Background: Cytogenetic aberrations such as deletion of chromosome 5q (del(5q)) represent key elements in routine clinical diagnostics of haematological malignancies. Currently established methods such as metaphase cytogenetics, FISH or array-based approaches have limitations due to their dependency on viable cells, high costs or semi-quantitative nature. Importantly, they cannot be used on low abundance DNA. We therefore aimed to establish a robust and quantitative technique that overcomes these shortcomings.
Methods: For precise determination of del(5q) cell fractions, we developed an inexpensive multiplex-PCR assay requiring only nanograms of DNA that simultaneously measures allelic imbalances of 12 independent short tandem repeat markers.
Results: Application of this method to n=1142 samples from n=260 individuals revealed strong intermarker concordance (R²=0.77–0.97) and reproducibility (mean SD: 1.7%). Notably, the assay showed accurate quantification via standard curve assessment (R²>0.99) and high concordance with paired FISH measurements (R²=0.92) even with subnanogram amounts of DNA. Moreover, cytogenetic response was reliably confirmed in del(5q) patients with myelodysplastic syndromes treated with lenalidomide. While the assay demonstrated good diagnostic accuracy in receiver operating characteristic analysis (area under the curve: 0.97), we further observed robust correlation between bone marrow and peripheral blood samples (R²=0.79), suggesting its potential suitability for less-invasive clonal monitoring.
Conclusions: In conclusion, we present an adaptable tool for quantification of chromosomal aberrations, particularly in problematic samples, which should be easily applicable to further tumour entities.
Internationale sprachwissenschaftliche Konferenz "Korpuslinguistik Deutsch-Tschechisch kontrastiv" in Sambachshof und Würzburg, 06.-08. Oktober 2009 (Iva Kratochvílová, Norbert Richard Wolf)
"Tschechen und Deutsche im 20. und 21. Jahrhundert. Neue Sichtweisen auf alte Probleme." Deutsch-tschechisches Seminar in Sankelmark, 09.-11. Oktober 2009 (Jarmila Jehličková)
Von der Grenze zum Dazwischen. Ein tschechisch-österreichisches Projekt zur Grenze und der Veränderung ihrer Wahrnehmung in Wien, 9.-11. November 2009 und Brünn 7.-10. Dezember 2009 (Michaela Kropik, Katharina Wessely)
Bericht über den V. Germanisten-Kongress in Sevilla, 16.-18. Dezember 2009 (Fernando Magallanes)
Bericht über die Linguistik-Tage in Freiburg im Breisgau, 02.-04. März 2010 (Martin Lachout)
Sprachliches Wissen zwischen Lexikon und Grammatik. Bericht über die 46. Jahrestagung des Instituts für Deutsche Sprache in Mannheim, 09.-11. März 2010 (Veronika Kotůlková)
"Mittlerin aus Europas Mitte" – 3. MGV-Kongress in Wien, 08.-10. April 2010 (Manfred Glauniger)
"Gedichte und Geschichte – Zur poetischen und politischen Rede in Österreich". Tagung der Franz Werfel-Stipendiaten und –Stipendiatinnen in Wien, 16.–17. April 2010 (Roman Kopřiva)
Binationales Kolloquium zur Problematik der Migrationsformen im 20. und 21. Jahrhundert in Geschichte und Kunst in Ústí nad Labem, 22.-24. März 2010 und Linz 04.-07. Mai 2010 (Jarmila Jehličková)
Ein "hinternationaler" Schriftsteller aus Böhmen: Dritte internationale Johannes-Urzidil-Konferenz in Ústí nad Labem, 05.-08. Mai 2010 (Vera Schneider)
"Wir sind Tschechinnen, wir schreiben Deutsch!" – Öffentliche Gesprächsrunde mit deutschsprachigen Autorinnen in Prag, 13. Mai 2010 (Jenifer Johanna Becker)
"Überkreuzungen. Verhandlungen kultureller, ethnischer, religiöser und geschlechtlicher Identitäten in österreichischer Literatur und Kultur." MALCA-Tagung in Wien, 22.-25. Mai 2010 (Daniela Drobna, Katharina Haderer, Natalie Lamprecht, Friedrich Teutsch, Esther Wratschko)
Chordomas are rare bone tumors with few therapeutic options. Here we show, using whole-exome and genome sequencing within a precision oncology program, that advanced chordomas (n = 11) may be characterized by genomic patterns indicative of defective homologous recombination (HR) DNA repair and alterations affecting HR-related genes, including, for example, deletions and pathogenic germline variants of BRCA2, NBN, and CHEK2. A mutational signature associated with HR deficiency was significantly enriched in 72.7% of samples and co-occurred with genomic instability. The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib, which is preferentially toxic to HR-incompetent cells, led to prolonged clinical benefit in a patient with refractory chordoma, and whole-genome analysis at progression revealed a PARP1 p.T910A mutation predicted to disrupt the autoinhibitory PARP1 helical domain. These findings uncover a therapeutic opportunity in chordoma that warrants further exploration, and provide insight into the mechanisms underlying PARP inhibitor resistance.
Due to the increasingly heterogeneous trajectories of aging, gerontology requires theoretical models and empirical methods that can meaningfully, reliably, and precisely describe, explain, and predict causes and effects within the aging process, considering particular contexts and situations. Human behavior occurs in contexts; nevertheless, situational changes are often neglected in context-based behavior research. This article follows the tradition of environmental gerontology research based on Lawton’s Person-Environment-Interaction model (P-E model) and the theoretical developments of recent years. The authors discuss that, despite an explicit time component, current P-E models could be strengthened by focusing on detecting P-E interactions in various everyday situations. Enhancing Lawton’s original formula via a situationally based component not only changes the theoretical perspectives on the interplay between person and environment but also demands new data collection approaches in empirical environmental research. Those approaches are discussed through the example of collecting mobile data with smartphones. Future research should include the situational dimension to investigate the complex nature of person environment interactions.
Die Digitalisierung weiter Teile der Lebenswelt ist vor allem mit der Verbreitung und extensiven Nutzung des Smartphones verknüpft. Eine Mehrzahl der älteren Menschen in Deutschland nutzt Smartphones selbstverständlich im Alltag. Die vorliegende Studie adressiert erstens wie stark sich das Smartphone bereits in den Alltag älterer Menschen als vergleichsweise neue Technologie eingeschrieben hat. Im Mittelpunkt steht dabei, welche Funktionen genutzt werden, wie oft und wann zum Smartphone gegriffen wird und welche Gemeinsamkeiten und Unterschiede in der Nutzung identifizierbar sind. Darüber hinaus wird zweitens der Zusammenhang zwischen alltäglicher Smartphonenutzung, Medienkompetenz und technikbezogenen Einstellungen in den Blick genommen. Drittens geht die Studie der Frage nach inwiefern die Smartphonenutzung mit zentralen Variablen der Lebensqualität im Alter, der sozialer Eingebundenheit sowie dem subjektiven Wohlbefinden assoziiert ist. Die vorliegende Arbeit ist eine quantitativ empirische Studie, die einem mikrolängsschnittlichem Design folgt. Zur Beantwortung der Forschungsfragen wurden objektive Nutzungsdaten, Daten aus einem ambulanten Assessment sowie Daten eines querschnittlichen Fragebogens kombiniert. Die Ergebnisse zeigen, dass die Befragten älteren Menschen im Hinblick auf Nutzungsdauer, -intensität als auch inhaltlicher Vielfalt hohe inter- als auch intraindividuelle Unterschiede aufwiesen. Gemeinsamkeiten der Nutzung waren die Kommunikation oder Alltagsorganisation. Das Smartphone wurde aber auch zum Spielen oder für gesundheitsbezogene Handlungen genutzt. Gleichzeitig ging eine zeitlich intensive auch mit einer inhaltlich breit gefächerten Nutzung einher. Die Unterschiede in der Nutzung konnten primär durch technikbezogene Einstellungen und deklarative Wissensbestände zu Computer und Smartphone erklärt werden. Intensivnutzer wiesen positivere Einstellungen gegenüber Technik auf und verfügten über höhere Wissensbestände. Trotz intensiver Nutzung des Smartphones zur Kommunikation zeigte sich kein klarer Zusammenhang mit sozialer Eingebundenheit und subjektivem Wohlbefinden. Vielmehr konnte in diesem Kontext die wahrgenommene Qualität der erlebten sozialen Beziehungen als zentraler Prädiktor identifiziert werden. Zusammengenommen zeigte sich eine tiefe Integration des Smartphones in den Alltag älterer Smartphonenutzer.
Aim: To compare clinical success and complications of uncovered self-expanding metal stents (SEMS) vs covered SEMS (cSEMS) in obstruction of the small bowel.
Methods: Technical success, complications and outcome of endoscopic SEMS or cSEMS placement in tumor related obstruction of the duodenum or jejunum were retrospectively assessed. The primary end points were rates of stent migration and overgrowth. Secondary end points were the effect of concomitant biliary drainage on migration rate and overall survival. The data was analyzed according to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.
Results: Thirty-two SEMS were implanted in 20 patients. In all patients, endoscopic stent implantation was successful. Stent migration was observed in 9 of 16 cSEMS (56%) in comparison to 0/16 SEMS (0%) implantations (P = 0.002). Stent overgrowth did not significantly differ between the two stent types (SEMS: 3/16, 19%; cSEMS: 2/16, 13%). One cSEMS dislodged and had to be recovered from the jejunum by way of laparotomy. Time until migration between SEMS and cSEMS in patients with and without concomitant biliary stents did not significantly differ (HR = 1.530, 95%CI 0.731-6.306; P = 0.556). The mean follow-up was 57 ± 71 d (range: 1-275 d).
Conclusion: SEMS and cSEMS placement is safe in small bowel tumor obstruction. However, cSEMS is accompanied with a high rate of migration in comparison to uncovered SEMS.
